On 21 September 2026, the US Centers for Medicare & Medicaid Services (CMS) published preliminary laboratory payment data for 2027 and estimated that aligning Medicare rates more closely with private payer prices could save taxpayers approximately $1 billion a year. This is a proposal with a comment period, rather than an enacted schedule. Its significance for employer benefits lies in the relationship between public tariffs, commercial contracts and access to diagnostic services.

CMS reports that the new private payer weighted medians are, on average, around 16% below its 2026 Clinical Laboratory Fee Schedule rates for comparable tests. This comparison does not mean that every test, provider or health plan will experience a 16% price cut. Of 1,528 codes with a private payer median, 1,171 have a lower median than the existing Medicare rate, 186 a higher one and 169 the same rate; two lack a comparable 2026 rate. The figures refer to the codes in this data cycle, not to all medical spending.

How the new benchmark is calculated

Under the Protecting Access to Medicare Act, applicable laboratories report private payer prices and test volumes. CMS calculates a weighted median by test code and generally uses it to set Medicare laboratory payments. The 2027 proposal is based on prices collected from January 2025 through June 2025 and reported between May and July 2026. CMS says 6,411 laboratories submitted data, with 6,304 used after exclusions; 1,528 of 1,947 applicable codes have a weighted median based on the submissions.

The data are not a simple national price list for employers. They combine contracts with different insurers and laboratory types, while individual employer plans still pay according to their own provider agreements and claims arrangements. CMS excluded duplicate records and certain extreme values, and is consulting on that treatment. Codes without sufficient private payer data require separate pricing methods. The composition of the sample, the choice of tests and any response from laboratories therefore matter as much as the headline average.

There is also a statutory limit on the pace of change. Medicare payments for an existing clinical diagnostic test cannot fall by more than 15% in a year from 2027 through 2029. CMS expects final rates in November 2026, effective on 1 January 2027, after a 30 day period for comments. Employers should avoid treating the preliminary figures as contracted savings in a 2027 budget.

What employers and insurers should examine

For self funded employers, the immediate question is not whether Medicare will pay less, but whether laboratory contracts, network pricing formulas or out of network payment rules use Medicare as a reference. A contract set at a multiple of the Medicare fee schedule could respond mechanically when that schedule changes; a fixed commercial fee schedule may not. Insurers and third party administrators should be able to identify which tests and contracts are affected before projecting a benefit to the plan.

A useful review starts with claims data: test code, unit price, provider type, volume and member location. The plan can compare common tests with the proposed CMS figures, flag tests with rising utilisation, and ask its network manager how laboratory contracts will be renegotiated. It should also check whether savings at one site are offset by higher facility fees, billing through another setting, or changes in patient access. A lower reimbursement rate is not automatically a lower total episode cost.

The benefits perspective includes quality and employee experience. Delayed or unavailable diagnostics can raise downstream costs and frustrate care, particularly in oncology and chronic disease. Any procurement decision should test turnaround times, geographic access, laboratory quality and the consequences for members, alongside price. Those measures should be reviewed with the insurer, administrator and clinical adviser rather than derived from payment data alone.

An early signal for multinational benefits governance

For multinational employers, this is a useful example of how one national public payer can use private market data to reset its own benchmark. The direction of influence may then run back through commercial contracts where public rates serve as reference points. That feedback loop is an analytical possibility, not an outcome that CMS has quantified for employer plans.

GBV’s practical recommendation is to build a small laboratory cost dashboard for US plans before the final November rates arrive. Separate price from utilisation, list contracts indexed to Medicare, assess member access and document the assumptions behind any projected savings. This turns a federal payment announcement into a controlled employer benefits decision, without claiming that Medicare’s forecast of taxpayer savings belongs to private plans.